Parmigiani
Corrado Saverio Parmigiani, Correggio (reggio Emilia) IT
Patent application number | Description | Published |
---|---|---|
20150069661 | PROCESS AND APPARATUS FOR COMPRESSION-FORMING OF THERMOPLASTIC OBJECTS - The process includes a die comprising a bottom die ( | 03-12-2015 |
20150102527 | PRESSURE-FORMING PROCESS FOR THERMOPLASTIC OBJECTS - A compression forming process includes use of a die comprising: a bottom die ( | 04-16-2015 |
Corrado Saverio Parmigiani, Reggio Emilia IT
Patent application number | Description | Published |
---|---|---|
20100094297 | SURGICAL BONE MILLING INSTRUMENT - A surgical bone milling instrument, suited to operate in a hole formed in a bone, comprising a milling element ( | 04-15-2010 |
20100121330 | SURGICAL BONE MILLING INSTRUMENT - A surgical bone milling instrument, for operating in a hole formed in a bone, comprising a milling element ( | 05-13-2010 |
Corrado Saverio Parmigiani, Correggio IT
Patent application number | Description | Published |
---|---|---|
20100237537 | COMPRESSION MOULDING METHOD FOR REALISING THERMOPLASTIC PRODUCTS - A method for realising thermoplastic products, comprising: use of a granular material comprising granules of thermoplastic polymers; inserting a dose (M) of the granular material internally of the chamber ( | 09-23-2010 |
20130285288 | COMPRESSION MOULDING THERMOPLASTIC - An apparatus includes one or more die groups which are movable independently of one another, each including a female part having a matrix cavity and a male part destined to penetrate into the cavity such as to define a forming chamber of the product, the cavity configured to contain a batch of material. The apparatus further includes a heating station having a heater to bring the plastic material to the fluid state, and a die group cooling station downstream of the heating station. The die groups are free to be cyclically inserted in the heating station and subsequently transferred to the cooling station. A thrust group is associated to a respective die group and is configured to provide a thrust for penetrating the male part into the cavity during the stage of forming the product, the thrust group being integral with the respective die-group in displacements during the operations performed. | 10-31-2013 |
20160089192 | HEAD FOR HOLDING A NAIL DESTINED FOR BONE IMPLANTOLOGY AND KIT THEREOF | 03-31-2016 |
20160089218 | DEVICE FOR GENERATING AN IMPULSIVE FORCE AND NAIL GUN THEREOF | 03-31-2016 |
Francesca Parmigiani, Southampton GB
Patent application number | Description | Published |
---|---|---|
20130208334 | Optical Signal Processing - An optical regenerator for regenerating a multi-level phase encoded signal. A first non-linear medium (HNLF | 08-15-2013 |
20130301661 | Optical Signal Processing - An optical device, suitable for use either as a coherent receiver or analog-to-digital converter, of optical phase modulated signals borne on a carrier. The signal is four-wave mixed with a pump to generate a non-linear comb of a series of harmonic components of the signal. The modulation-free carrier is also combined with the pump to generate an equivalent linear comb matched in frequency to the components of the non-linear comb. The harmonic and modulation-free components are linearly combined so they interfere in a pairwise manner, and then the interfered frequency components are separated out in an optical wavelength division demultiplexer into a plurality of frequency-specific optical output channels. A plurality of photodetectors connected to respective ones of the optical output channels then converts the analog values in each channel to respective electronic signals which are then digitized using a processor into binary digits using a thresholding process. | 11-14-2013 |
Giovanni Parmigiani, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20120202207 | GENETIC ALTERATIONS IN ISOCITRATE DEHYDROGENASE AND OTHER GENES IN MALIGNANT GLIOMA - We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas. | 08-09-2012 |
Giovanni Parmigiani, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20090123928 | Genomic Landscapes of Human Breast and Colorectal Cancers - Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalogue the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene “mountains” and a much larger number of gene “hills” that are mutated at low frequency. We describe statistical and bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy. | 05-14-2009 |
20110229479 | GENETIC ALTERATIONS IN ISOCITRATE DEHYDROGENASE AND OTHER GENES IN MALIGNANT GLIOMA - We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas. | 09-22-2011 |
20130196312 | GENOMIC LANDSCAPES OF HUMAN BREAST AND COLORECTAL CANCERS - Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalogue the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene “mountains” and a much larger number of gene “hills” that are mutated at low frequency. We describe statistical and bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy. | 08-01-2013 |
20140187764 | GENETIC ALTERATIONS IN ISOCITRATE DEHYDROGENASE AND OTHER GENES IN MALIGNANT GLIOMA - We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas. | 07-03-2014 |
20140377754 | Genomic Landscapes of Human Breast and Colorectal Cancers - Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalogue the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene “mountains” and a much larger number of gene “hills” that are mutated at low frequency. We describe statistical and bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy. | 12-25-2014 |
Giovanni Parmigiani, Brookline, MA US
Patent application number | Description | Published |
---|---|---|
20120115735 | Pathways Underlying Pancreatic Tumorigenesis and an Hereditary Pancreatic Cancer Gene - There are currently few therapeutic options for patients with pancreatic cancers and new insights into the pathogenesis of this lethal disease are urgently needed. To this end, we performed a comprehensive analysis of the genes altered in 24 pancreatic tumors. First, we determined the sequences of 23,781 transcripts, representing 20,583 protein-encoding genes, in DNA from these tumors. Second, we searched for homozygous deletions and amplifications using microarrays querying ˜one million single nucleotide polymorphisms in each sample. Third, we analyzed the transcriptomes of the same samples using SAGE and next-generation sequencing-by-synthesis technologies. We found that pancreatic cancers contain an average of 63 genetic alterations, of which 49 are point mutations, 8 are homozygous deletions, and 6 are amplifications. Further analyses revealed a core set of 12 regulatory processes or pathways that were each genetically altered in 70% to 100% of the samples. The data suggest that dysregulation of this core set of pathways is responsible for the major features of pancreatic tumorigenesis. | 05-10-2012 |
Giovanni Luigi Parmigiani, Brookline, MA US
Patent application number | Description | Published |
---|---|---|
20160047000 | METHODS AND SYSTEMS FOR TREATMENT OF OVARIAN CANCER - As described herein, the inventors have identified gene signatures which permit the identification of patients who will benefit from (e.g. have optimal outcomes) cytoreductive surgery as treatment for ovarian cancer. Accordingly, provided herein are methods of treatment, assays, and systems relating to ovarian cancer and the administration of cytoreductive surgery. In one aspect, the technology described herein relates to a method of treatment comprising, detecting, in a sample obtained from a subject in need of treatment for ovarian cancer, the level of activation of at least one pathway, and administering cytoreductive surgery to the subject if the level of activation is not increased relative to a reference level. | 02-18-2016 |
Raphael Bessa Parmigiani, Sao Paulo City BR
Patent application number | Description | Published |
---|---|---|
20120276147 | CTSP CANCER-TESTIS ANTIGENS - The invention relates to CTSP polypeptides and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis, prognosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, CTSP-1. | 11-01-2012 |
Roberto Maria Parmigiani, Magenta (milano) IT
Patent application number | Description | Published |
---|---|---|
20080269669 | Apparatus and Method for Subcutaneous Gas Delivery for Therapeutic Purpose - An apparatus ( | 10-30-2008 |
Stefano Parmigiani, Fidenza IT
Patent application number | Description | Published |
---|---|---|
20100049104 | DEVICE FOR THE TREATMENT OF TINNITUS - A device for the treatment of tinnitus, comprising generator means able to generate an audio signal, and transducer means connected to the generator means in order to reproduce the audio signal. The device also comprises filter means interposed between the generator means and the transducer means in order to filter and substantially suppress the audio signal at least in correspondence with an interval of frequencies around the dominant frequency (Ft) of tinnitus, so as to obtain a silent window (silent band) having a selected width or amplitude around said dominant frequency (Ft) of tinnitus. | 02-25-2010 |